other material
confidence high
sentiment positive
materiality 0.55
Evofem signs manufacturing deal with Zhaoke for PHEXX, targets 40%+ cost cut
Evofem Biosciences, Inc.
- Manufacturing agreement with Zhaoke (Hong Kong) and Zhaoke (Guangzhou) dated Sept 17, 2026.
- Expected to reduce PHEXX unit costs by 40% or more after FDA approval, improving economics.
- Plans sNDA submission to FDA in mid-2027 for PHEXX from the new facility.
- Adds second supply source to boost flexibility and capacity for US and global growth.